PharmaCyte CEO reports open-market stock purchases

PharmaCyte Biotech, Inc. CEO and President Joshua Silverman reported multiple open-market purchases of the company’s common stock.

Rhea-AI Filing Summary

PharmaCyte Biotech, Inc. CEO and President Joshua Silverman reported multiple open-market purchases of the company’s common stock. On January 5, 2026, he bought 30,000 shares at $0.7831 per share. On January 6, 2026, he bought another 30,000 shares at $0.7889 per share, and on January 7, 2026, he bought 40,000 shares at $0.8329 per share.

After these transactions, Silverman directly beneficially owned 416,250 shares of PharmaCyte common stock and indirectly beneficially owned an additional 50,000 shares through JNS Holdings Group LLC.

Insider Trade Summary

Net Buyer: 100,000 shares

Net Buy 4 txns

Insider Silverman Joshua

Role CEO and President

Bought 100,000 shs ($80K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	40,000	$0.8329	$33K
Purchase	Common Stock	30,000	$0.7889	$24K
Purchase	Common Stock	30,000	$0.7831	$23K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 416,250 shares (Direct); Common Stock — 50,000 shares (Indirect, JNS Holdings Group LLC)

FAQ

What did PharmaCyte Biotech (PMCB) disclose in this Form 4?

The filing reports that CEO and President Joshua Silverman purchased shares of PharmaCyte Biotech, Inc. common stock in several open-market transactions in January 2026, and it updates his total beneficial ownership.

How many PharmaCyte (PMCB) shares did the CEO buy and at what prices?

Joshua Silverman bought 30,000 shares at $0.7831 on January 5, 30,000 shares at $0.7889 on January 6, and 40,000 shares at $0.8329 on January 7, 2026.

How many PharmaCyte (PMCB) shares does Joshua Silverman own after these trades?

Following the reported transactions, Joshua Silverman directly beneficially owned 416,250 shares of PharmaCyte common stock and indirectly beneficially owned 50,000 shares through JNS Holdings Group LLC.

Were any of Joshua Silverman’s PharmaCyte (PMCB) holdings reported as indirect?

Yes. The Form 4 shows 50,000 shares of PharmaCyte common stock held indirectly through JNS Holdings Group LLC, in addition to his directly held shares.

What role does Joshua Silverman hold at PharmaCyte Biotech (PMCB)?

Joshua Silverman is reported as both a Director and an Officer of PharmaCyte Biotech, Inc., serving as the company’s CEO and President.

Does this PharmaCyte (PMCB) Form 4 mention any derivative securities?

The section for derivative securities is included in the form template, but no specific derivative transactions or holdings are reported in the provided content.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/07/2026 - 05:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silverman Joshua

(Last) (First) (Middle)

C/O PHARMACYTE BIOTECH, INC.

3960 HOWARD HUGHES PARKWAY, SUITE 500

(Street)

LAS VEGAS NV 89169

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [ PMCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		P		30,000	A	$0.7831	346,250	D
Common Stock	01/06/2026		P		30,000	A	$0.7889	376,250	D
Common Stock	01/07/2026		P		40,000	A	$0.8329	416,250	D
Common Stock								50,000	I	JNS Holdings Group LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1, Power of Attorney

	/s/ Joshua N. Silverman	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.